Albumin as Excipient Sales

Albumin as Excipient Sales Market Outlook

The global Albumin as Excipient market is projected to reach approximately USD 5.3 billion by 2035, growing at a CAGR of about 6.5% from 2025 to 2035. This growth can be attributed to the increasing demand for biologics, advancements in drug delivery systems, and the rising prevalence of chronic diseases that necessitate the use of albumin as a stabilizer and carrier in various formulations. Additionally, the growing biopharmaceutical sector has further propelled the need for effective excipients to enhance the solubility and stability of therapeutic proteins. These factors, combined with a robust pipeline of new drugs, are significantly driving the albumin excipient market's expansion.

Growth Factor of the Market

One of the primary growth factors for the Albumin as Excipient market is the rapid advancements in biotechnology and pharmaceutical research that are increasingly relying on complex molecules requiring effective excipients for their formulation. As the biopharmaceutical industry continues to evolve, there is a greater emphasis on the formulation of therapeutic proteins and monoclonal antibodies, which often utilize albumin to enhance stability and bioavailability. Furthermore, the trend towards personalized medicine is creating new opportunities for albumin-based formulations, particularly in the treatment of cancer and autoimmune diseases, where targeted drug delivery is crucial. The expansion of research activities in the field of drug delivery systems also supports the increasing application of albumin as a favorable excipient. In addition, the growing awareness regarding the benefits of albumin in various applications, such as food and cosmetics, has opened new market segments. The increasing consumer preference for natural and biocompatible excipients is further driving the market growth.

Key Highlights of the Market

• Projected market size of USD 5.3 billion by 2035.
• CAGR of 6.5% from 2025 to 2035.
• Significant demand from the biopharmaceutical sector.
• Increasing focus on drug delivery systems leveraging albumin.
• Emerging applications in food and cosmetic industries.

By Product Type

Human Serum Albumin :

Human Serum Albumin (HSA) is a vital product type in the Albumin as Excipient market, primarily utilized in drug formulations and therapeutic applications. HSA is derived from human blood and is known for its excellent biocompatibility and ability to bind various drug molecules, enhancing their solubility and stability. The increasing incidence of liver diseases and other conditions requiring intravenous therapy has significantly contributed to HSA's demand. Its application as a carrier for drugs, particularly in oncological treatments, has propelled its market growth. Furthermore, regulatory approvals and advancements in purification technologies have made HSA more accessible, thereby expanding its use across pharmaceutical applications.

Bovine Serum Albumin :

Bovine Serum Albumin (BSA) is another prominent product type used as an excipient in the pharmaceutical and biotechnology sectors. BSA is derived from bovine blood and offers similar stabilizing and solubilizing properties as HSA but at a lower cost. Its widespread use in laboratory research, diagnostics, and vaccine development has driven its demand in the market. BSA's role as a stabilizer, particularly in the formulation of vaccines and therapeutic proteins, has made it indispensable in biopharmaceutical applications. The increasing focus on vaccine development and the growing bioresearch activities worldwide are expected to fuel the growth of the BSA segment within the albumin excipients market.

Recombinant Albumin :

Recombinant Albumin is a product type that has gained traction due to its consistent quality and reduced risk of transmission of infectious agents, compared to plasma-derived albumins. This type of albumin is produced through recombinant DNA technology, ensuring a high degree of purity and control over the production process. The demand for recombinant albumin is rising steadily in pharmaceutical formulations, particularly in the development of monoclonal antibodies and other biologics. Additionally, its potential use in tissue engineering and regenerative medicine is driving research and development, thus expanding its market footprint. This segment is anticipated to witness substantial growth in the coming years, especially with increasing safety concerns associated with animal-derived products.

Plant-Derived Albumin :

Plant-Derived Albumin is an emerging product type that is gaining popularity due to the increasing consumer preference for vegan and sustainable alternatives. Derived from various plant sources, such as legumes, this type of albumin is garnering attention for its potential applications in pharmaceuticals, food, and cosmetics. The growing awareness about health and wellness is leading to a shift towards plant-based formulations, thereby stimulating the demand for plant-derived albumin as an excipient. Furthermore, advancements in extraction and purification technologies are enhancing the availability and functionality of plant-derived albumins, presenting numerous opportunities for innovation within the market.

Others :

The "Others" category encompasses a range of less common but relevant albumin types that are utilized in specific applications across industries. This may include albumins sourced from other animal species or engineered forms of albumin designed for specialized applications. While the volume of this segment may not be as significant as the main types, its contribution to niche markets and specific therapeutic applications should not be overlooked. The ongoing research and development efforts aimed at exploring new sources and formulations of albumin are expected to foster growth in this category, particularly in targeted delivery systems and personalized medicine.

By Application

Pharmaceuticals :

The pharmaceutical application segment represents one of the largest market shares for albumin excipients, as it plays a crucial role in the formulation of various drug products. Albumin is primarily used as a stabilizer and carrier for therapeutic proteins, enzymes, and vaccines, ensuring their efficacy and safety during storage and administration. The increasing prevalence of chronic diseases and the rising demand for biologics are driving the growth of this segment. Moreover, the incorporation of albumin in injectable formulations enhances the solubility and bioavailability of drugs, making it indispensable for many pharmaceutical applications.

Biotechnology :

In the biotechnology sector, albumin is utilized in the development of biopharmaceuticals and therapeutic proteins, enhancing their stability and facilitating their delivery. The growing focus on recombinant proteins and monoclonal antibodies has significantly increased the demand for albumin as an excipient in biotechnological applications. Its role in protecting these sensitive molecules from aggregation and degradation is well recognized, leading to its widespread adoption in bioprocessing and formulation. As the biotechnology landscape evolves, the application of albumin in advanced therapies, such as gene therapy and personalized medicine, is expected to further drive growth in this segment.

Food & Beverage :

The food and beverage industry is increasingly recognizing the value of albumin as an excipient, particularly in the formulation of protein-rich products and food additives. Albumin is used for its emulsifying, stabilizing, and foaming properties, enhancing the texture and quality of various food products. The rising consumer demand for protein-enriched foods and the trend towards natural and clean-label products are propelling the growth of this segment. Additionally, albumin's potential use in plant-based food applications is opening new avenues for market expansion, catering to the growing vegan and health-conscious consumer base.

Cosmetics :

In the cosmetics industry, albumin is increasingly being incorporated as an ingredient in skincare and cosmetic formulations due to its film-forming and moisture-retaining properties. It provides texture and stability to products, enhancing their overall performance. The growing demand for natural and biocompatible ingredients in cosmetics is driving the use of albumin as a key excipient. Furthermore, the increasing trend towards anti-aging and skin rejuvenation products that leverage the properties of albumin is expected to contribute significantly to market growth in this sector.

Others :

The "Others" category under applications includes various sectors where albumin is utilized in specialized applications, such as diagnostics and research laboratories. This segment may encompass applications in areas such as veterinary medicine, medical devices, and specialized dietary supplements. While this segment may not constitute the largest share of the market, its importance in niche applications and the ongoing research for novel uses of albumin are indicative of the expanding scope of the albumin excipient market.

By Distribution Channel

Online Stores :

Online stores have emerged as a significant distribution channel for albumin excipients, providing a platform for manufacturers and suppliers to reach a wider audience. The convenience and accessibility offered by online shopping have led to an increase in purchasing behavior among consumers, particularly during the recent pandemic. E-commerce platforms facilitate easy comparison of products, pricing, and customer reviews, enhancing the buying experience. Additionally, the growing trend of direct-to-consumer sales and increasing digital marketing strategies by companies are expected to propel the growth of the online distribution channel for albumin.

Specialty Stores :

Specialty stores serve as a critical distribution channel for albumin excipients, particularly in the biotechnology and pharmaceutical sectors. These stores often cater to professionals seeking high-quality ingredients for specific applications and formulations. The personalized service, expert advice, and specialized products offered by these retailers are key advantages that attract customers. As the demand for customized solutions in drug formulation and bioprocessing continues to rise, specialty stores are likely to play an increasingly significant role in the albumin excipient market.

Drug Stores :

Drug stores represent an essential distribution channel for albumin excipients, especially for related pharmaceutical products. These stores often stock a range of excipients and ingredients that are critical for compounding and preparing medications. As the demand for personalized medicine and compounded pharmaceuticals grows, drug stores are enhancing their offerings to include a variety of excipients, including albumin. The collaboration between drug stores and pharmaceutical companies to provide essential ingredients for drug formulations is expected to foster growth in this segment.

Hospitals & Clinics :

Hospitals and clinics play a vital role in the distribution of albumin excipients, particularly for therapeutic uses in patient treatments. These healthcare facilities require high-quality, reliable excipients for the preparation of injectable medications and albumin-based therapies. The increasing incidence of chronic diseases and the subsequent rise in hospitalization rates are driving the need for albumin in medical settings. As healthcare providers increasingly focus on improving patient outcomes, the demand for albumin excipients in hospitals and clinics is projected to grow.

Others :

The "Others" category in distribution channels includes various unconventional and niche outlets that may sell albumin excipients, such as industrial suppliers and research institutions. These channels cater to specialized markets and may focus on specific applications or industries requiring albumin. Although this segment may not represent a significant portion of the overall market, its existence underscores the diverse sourcing opportunities available for albumin products.

By Ingredient Type

Stabilizer :

As a stabilizer, albumin plays a crucial role in ensuring the integrity and efficacy of various formulations across pharmaceutical and biopharmaceutical applications. It aids in preventing the aggregation of proteins and other sensitive molecules, thus maintaining their stability during storage and administration. The increasing demand for stable and effective drug formulations is driving the growth of the stabilizer segment, particularly in injectable products. With the rise of biologics and complex drug molecules, the role of albumin as a stabilizing agent is becoming increasingly significant, positioning it as a key ingredient in various therapeutic applications.

Emulsifier :

Albumin's emulsifying properties are essential in the formulation of various products, particularly in pharmaceuticals and food applications. It helps to stabilize oil-in-water emulsions, improving the texture and consistency of formulations. The demand for emulsifiers is on the rise due to the growing need for stable and high-quality products in the food and beverage industry, as well as in pharmaceuticals. As consumers increasingly seek products with natural and clean-label ingredients, the role of albumin as a plant-based emulsifier is gaining prominence, driving growth in this segment.

Coating Agent :

As a coating agent, albumin is utilized in various pharmaceutical formulations to enhance drug delivery and improve product aesthetics. It provides a protective layer around active ingredients, preventing degradation and controlling the release of drugs. The increasing focus on developing controlled-release formulations is driving the demand for albumin as a coating agent. Furthermore, the use of albumin in the development of novel drug delivery systems is expected to open new opportunities for growth in this segment, particularly for targeted therapies and personalized medicine.

Diluent :

Albumin also serves as a diluent in various formulations, particularly in injectable products, where it aids in adjusting the concentration of active ingredients to achieve the desired therapeutic effect. The increasing prevalence of chronic diseases and the rising demand for injectable medications are driving the growth of the diluent segment. As more biologics and complex drugs are brought to market, the reliance on albumin as a diluent is expected to increase, further solidifying its position as a key ingredient in pharmaceutical formulations.

Others :

The "Others" category in ingredient types encompasses various niche applications where albumin may serve unique roles, including its use in diagnostics, research, and specialty formulations. While these applications may not dominate the market, they highlight the versatility of albumin as an excipient and its potential for innovation in diverse sectors. As research continues to uncover new uses and applications for albumin, this segment is anticipated to grow, contributing to the overall expansion of the albumin excipient market.

By Region

The North American region holds a significant share of the Albumin as Excipient market, accounting for approximately 35% of the total market. The growth in this region can be attributed to the strong presence of leading pharmaceutical and biotechnology companies, coupled with increasing investments in research and development activities. The demand for biologics and monoclonal antibodies in North America is driving the need for high-quality excipients like albumin. Additionally, favorable regulatory frameworks and innovations in drug delivery systems are further fueling market growth. The region is expected to maintain a robust CAGR of 6.4% throughout the forecast period due to ongoing advancements in biopharmaceuticals.

Europe is another key region in the Albumin as Excipient market, contributing approximately 30% of the global market share. The region is characterized by a well-established pharmaceutical industry and a growing focus on biotechnology. Countries like Germany, the UK, and France are leading contributors to market growth, driven by their strong research capabilities and demand for advanced therapeutics. The increasing adoption of albumin excipients in vaccine development and the rise in chronic disease prevalence are expected to further enhance growth in this region. The European market is projected to experience a CAGR of 6.0% from 2025 to 2035, reflecting a steady demand for albumin in various applications.

Opportunities

One of the most promising opportunities in the Albumin as Excipient market lies in the increasing focus on personalized medicine. As the healthcare landscape shifts towards tailored therapies that cater to individual patient needs, albumin's role as a versatile excipient is becoming more prominent. Its ability to enhance drug solubility, stability, and bioavailability makes it an excellent candidate for personalized formulations. Additionally, the growing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disorders is driving the demand for targeted therapies, which often rely on albumin for effective delivery. Innovations in albumin-based drug delivery systems have the potential to significantly improve therapeutic outcomes, making this an exciting area for investment and growth.

Another significant opportunity stems from the rise of the biopharmaceutical sector. As the development of biologics, including monoclonal antibodies and gene therapies, continues to expand, the demand for effective excipients like albumin is expected to increase. The challenges associated with formulating and delivering complex biologics require excipients that can enhance stability and improve solubility, making albumin an indispensable ingredient. Moreover, the push for environmentally sustainable solutions in pharmaceuticals is opening avenues for plant-derived albumins, catering to the growing market for natural and non-animal-derived ingredients. This trend towards sustainability is likely to foster innovation and new product development in the albumin excipient market.

Threats

Despite the robust growth prospects, the Albumin as Excipient market faces several challenges and threats that could hinder its expansion. One primary concern is the potential for supply chain disruptions, especially for animal-derived albumins sourced from bovine or human blood. Issues such as disease outbreaks, regulatory changes, and ethical considerations surrounding animal welfare can impact the availability and cost of these products. Moreover, the increasing scrutiny of animal-derived ingredients in pharmaceuticals and cosmetics is prompting a shift towards synthetic or plant-based alternatives, which could affect the traditional albumin market. Companies must navigate these challenges carefully to maintain supply continuity and meet evolving consumer preferences.

Another potential threat is the growing competition from alternative excipients and formulations that may offer similar or enhanced functionalities without the associated risks of albumin. The development of novel synthetic excipients, as well as the exploration of alternative natural ingredients, poses a competitive threat to traditional albumin applications. Companies in the albumin excipient market must continuously innovate and adapt to changing market dynamics to remain competitive. Furthermore, regulatory hurdles related to the approval and use of excipients in various applications can pose additional challenges, potentially delaying product launches and limiting market access.

Competitor Outlook

• Grifols S.A.
• Octapharma AG
• CSL Behring GmbH
• Shire (Takeda Pharmaceutical Company Limited)
• Merck KGaA
• Fresenius Kabi AG
• Proliant Biologicals
• Albumedix A/S
• Baxter International Inc.
• SeraCare Life Sciences
• Bioventus LLC
• Invitrogen (Thermo Fisher Scientific)
• Lonza Group AG
• Roche Diagnostics
• Kedrion S.p.A.

The competitive landscape of the Albumin as Excipient market is characterized by a diverse array of players, ranging from large multinational corporations to specialized niche companies. Major global firms such as Grifols S.A., CSL Behring, and Baxter International are at the forefront of albumin production and supply, leveraging their extensive resources and technological expertise to dominate the market. These companies have established strong distribution networks and are continuously investing in research and development to enhance albumin formulations and explore novel applications. The competitive pressure from these established players encourages innovation and improvement across the industry, driving advancements in albumin-based excipients.

In addition to the major players, a number of smaller companies and startups are emerging in the Albumin as Excipient market, focusing on specific niche applications and alternative albumin sources. Companies like Albumedix A/S and Proliant Biologicals are gaining traction by offering plant-derived albumins and recombinant products, catering to the growing demand for sustainable and ethical alternatives. These companies often emphasize research, product quality, and customer service, differentiating themselves in a competitive environment. As consumers increasingly prioritize transparency and sustainability, these niche players are poised to capture market share and drive innovation in the albumin excipient space.

Furthermore, strategic collaborations and partnerships are becoming increasingly common in the albumin market as companies seek to bolster their competitive advantage. Collaborations between pharmaceutical companies and excipient manufacturers can lead to the development of enhanced formulations and innovative drug delivery systems. For instance, partnerships between academia and industry players are fostering research initiatives aimed at discovering new applications for albumin in emerging therapeutic areas. This collaborative approach is not only enhancing the overall product offering but is also addressing the evolving market demands and regulatory challenges posed by the industry.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Merck KGaA
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Grifols S.A.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Albumedix A/S
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Bioventus LLC
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Octapharma AG
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Kedrion S.p.A.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Lonza Group AG
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 CSL Behring GmbH
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Fresenius Kabi AG
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Roche Diagnostics
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Proliant Biologicals
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 SeraCare Life Sciences
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Baxter International Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Invitrogen (Thermo Fisher Scientific)
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Shire (Takeda Pharmaceutical Company Limited)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Albumin as Excipient Sales Market, By Application
    • 6.1.1 Pharmaceuticals
    • 6.1.2 Biotechnology
    • 6.1.3 Food & Beverage
    • 6.1.4 Cosmetics
    • 6.1.5 Others
  • 6.2 Albumin as Excipient Sales Market, By Product Type
    • 6.2.1 Human Serum Albumin
    • 6.2.2 Bovine Serum Albumin
    • 6.2.3 Recombinant Albumin
    • 6.2.4 Plant-Derived Albumin
    • 6.2.5 Others
  • 6.3 Albumin as Excipient Sales Market, By Ingredient Type
    • 6.3.1 Stabilizer
    • 6.3.2 Emulsifier
    • 6.3.3 Coating Agent
    • 6.3.4 Diluent
    • 6.3.5 Others
  • 6.4 Albumin as Excipient Sales Market, By Distribution Channel
    • 6.4.1 Online Stores
    • 6.4.2 Specialty Stores
    • 6.4.3 Drug Stores
    • 6.4.4 Hospitals & Clinics
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Albumin as Excipient Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Albumin as Excipient Sales market is categorized based on

By Product Type

• Human Serum Albumin
• Bovine Serum Albumin
• Recombinant Albumin
• Plant-Derived Albumin
• Others

By Application

• Pharmaceuticals
• Biotechnology
• Food & Beverage
• Cosmetics
• Others

By Distribution Channel

• Online Stores
• Specialty Stores
• Drug Stores
• Hospitals & Clinics
• Others

By Ingredient Type

• Stabilizer
• Emulsifier
• Coating Agent
• Diluent
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Grifols S.A.
• Octapharma AG
• CSL Behring GmbH
• Shire (Takeda Pharmaceutical Company Limited)
• Merck KGaA
• Fresenius Kabi AG
• Proliant Biologicals
• Albumedix A/S
• Baxter International Inc.
• SeraCare Life Sciences
• Bioventus LLC
• Invitrogen (Thermo Fisher Scientific)
• Lonza Group AG
• Roche Diagnostics
• Kedrion S.p.A.